Top
Summary
All studies
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
All outcomes

Feedback
 
Analgesics⏵
Antiandrogens⏵
Antihistamines⏵
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Monoclonals⏵
Mpro inhibitors⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors⏵
TMPRSS2 inh.⏵
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
 
Top
..
All antroquinonol studies
..
Feedback
Home
c19early.org COVID-19 treatment researchAntroquinonolAntroquinonol (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta
Home Adoption Other Treatments
@CovidAnalysis

Outcomes in COVID-19 antroquinonol studies

Home
@CovidAnalysis
All
Studies
Feedback
All studies   Hospitalization   Serious outcomes   Recovery   Viral clearance   RCTs   All outcomes  
0 0.5 1 1.5+ All studies -200% 1 124 Improvement, Studies, Patients Relative Risk Hospitalization 2% 1 122 Viral clearance 7% 1 124 RCTs -200% 1 124 Late -200% 1 124 Antroquinonol for COVID-19 c19early.org November 2025 Favorsantroquinonol Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cheng (DB RCT) -200% 3.00 [0.12-72.3] progression 1/62 0/62 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.51 Late treatment -200% 3.00 [0.12-72.3] 1/62 0/62 200% higher risk All studies -200% 3.00 [0.12-72.3] 1/62 0/62 200% higher risk 1 antroquinonol COVID-19 study c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.51 Effect extraction pre-specified(most serious outcome) Favors antroquinonol Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cheng (DB RCT) 2% 0.98 [0.75-1.30] hosp. time 60 (n) 62 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.92 Late treatment 2% 0.98 [0.75-1.30] 60 (n) 62 (n) 2% lower risk All studies 2% 0.98 [0.75-1.30] 60 (n) 62 (n) 2% lower risk 1 antroquinonol COVID-19 hospitalization result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.92 Favors antroquinonol Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cheng (DB RCT) -200% 3.00 [0.12-72.3] progression 1/62 0/62 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.51 Late treatment -200% 3.00 [0.12-72.3] 1/62 0/62 200% higher risk All studies -200% 3.00 [0.12-72.3] 1/62 0/62 200% higher risk 1 antroquinonol COVID-19 serious outcome c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.51 Effect extraction pre-specified(most serious outcome) Favors antroquinonol Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cheng (DB RCT) -17% 1.17 [0.53-2.58] recov. time 62 (n) 62 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.72 Late treatment -17% 1.17 [0.53-2.58] 62 (n) 62 (n) 17% higher risk All studies -17% 1.17 [0.53-2.58] 62 (n) 62 (n) 17% higher risk 1 antroquinonol COVID-19 recovery result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.72 Favors antroquinonol Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cheng (DB RCT) 7% 0.93 [0.43-2.00] viral time 62 (n) 62 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.87 Late treatment 7% 0.93 [0.43-2.00] 62 (n) 62 (n) 7% lower risk All studies 7% 0.93 [0.43-2.00] 62 (n) 62 (n) 7% lower risk 1 antroquinonol COVID-19 viral clearance result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.87 Favors antroquinonol Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cheng (DB RCT) -200% 3.00 [0.12-72.3] progression 1/62 0/62 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.51 Late treatment -200% 3.00 [0.12-72.3] 1/62 0/62 200% higher risk All studies -200% 3.00 [0.12-72.3] 1/62 0/62 200% higher risk 1 antroquinonol COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.51 Effect extraction pre-specified(most serious outcome) Favors antroquinonol Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cheng (DB RCT) -200% 3.00 [0.12-72.3] progression 1/62 0/62 Improvement, RR [CI] Treatment Control Cheng (DB RCT) -17% 1.17 [0.53-2.58] recov. time 62 (n) 62 (n) Cheng (DB RCT) 6% 0.94 [0.77-1.14] recov. time 62 (n) 62 (n) Cheng (DB RCT) 2% 0.98 [0.75-1.30] hosp. time 60 (n) 62 (n) Cheng (DB RCT) 7% 0.93 [0.43-2.00] viral time 62 (n) 62 (n) Antroquinonol COVID-19 outcomes c19early.org November 2025 Favors antroquinonol Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0